Laddar...
Real-World Observational Review of Andexanet Alfa Prescribing and Utilization Outcomes at a Community Teaching Hospital
OBJECTIVES: Andexanet alfa is the first approved antidote in the management of life-threatening bleeds in patients treated with Xa inhibitors. The ANNEXA-4 study was successful in reducing factor Xa levels during time of administration but lacked correlation to improved patient outcomes. Given its n...
Sparad:
| I publikationen: | Crit Care Explor |
|---|---|
| Huvudupphovsmän: | , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Lippincott Williams & Wilkins
2021
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8021330/ https://ncbi.nlm.nih.gov/pubmed/33834167 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CCE.0000000000000356 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|